Brought to you by 
Portola Pharmaceuticals nets $131mm in initial public offering
19 Apr 2021
Executive Summary
Portola Pharmaceuticals Inc. (hematological and inflammatory disorders) has netted $131mm in its initial public offering. The company ended up selling 9.7mm shares (including the overallotment)--more than the 6.9mm planned--and priced the stock at $14.50, the mid-point of its $13-16 range.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Portola Pharmaceuticals nets $131mm in initial public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice